Insurance
Gene Therapies
Gene therapy has the potential to have a significant impact on health care costs by decreasing the lifetime expenses associated with organ transplants, hospital stays, and cancer and chronic disease treatments. For example, average undiscounted lifetime health care costs for a 45-year-old with sickle cell disease have reached $953,640. Meanwhile, a 2016 analysis in the…
Read MoreThe Legislative Landscape
As presidential candidates gear up for the 2020 elections, health reform (including single-payer systems) will continue to be an overarching and important topic of debate. At the same time, more immediate discussions are shaping benefits compliance trends now, such as expansion of health reimbursement arrangements (HRAs), the constitutionality of the Affordable Care Act (ACA), and…
Read MoreThe Pharmacy Scene
The 2018 pharmacy benefits landscape was dominated by mergers, acquisitions, and disrupters. There was unprecedented consolidation between Pharmacy Benefit Managers (PBMs) and health plans. As of this spring, five corporate giants in the health industry will control health insurance and pharmacy benefits for more than 125 million Americans across Medicare, Medicaid, and employer- based insurance.…
Read MoreCarve-Out & Delivery Model Strategies
Over the past few years, as employers looked to gain some semblance of control over soaring health care costs, there has been a focus on shifting more responsibility for those costs to employees. However, with a competitive labor market and health care cost increases outpacing wage increases, this practice has become unsustainable. Employers are now…
Read More